Biotech AI Startup Jobs

Varda Space Industries builds autonomous spacecraft that manufacture pharmaceuticals and other materials in microgravity before returning them to Earth, and sells orbital reentry and hypersonic-test services to government and commercial customers. Founded in 2021 by Will Bruey and Delian Asparouhov, the El Segundo-based company became a unicorn after its 2026 Series D.

A platform using artificial intelligence to support research in life sciences, chemical sciences, and materials sciences through autonomous AI labs building scientific superintelligence.

Biotech venture creation firm that invents and builds platform companies transforming human health and sustainability.

Osmo uses AI-powered olfactory intelligence to digitize and generate custom scent formulas, building the world's first AI-powered fragrance house with robotic production capabilities.

Periodic Labs is an AI research company focused on building autonomous AI scientists and software systems that accelerate scientific discovery.

Iambic Therapeutics is a clinical-stage biotech in San Diego using a physics-informed generative AI platform (NeuralPLexer, Enchant) to design and advance small-molecule cancer therapeutics. It has a lead HER2 inhibitor (IAM1363) in Phase 1/1b trials and major partnerships with Takeda, Jazz, and others, and filed an S-1 for a US IPO in September 2026.

Edison Scientific is a San Francisco-based AI company building autonomous "AI Scientists" for biology and chemistry research. Its core product, Kosmos, runs hundreds of research tasks in parallel — automating literature synthesis, data analysis, and molecular design — with the company claiming it compresses roughly six months of human research into a single day. Edison spun out of the nonprofit AI research lab FutureHouse in November 2025 and is led by CEO Sam Rodriques and CTO Andrew White.

Astromech is an AI-and-biology startup recruiting across genomics, evolutionary modeling, synthetic data, and alignment research to decode and simulate complex living systems.

Formation Bio (formerly TrialSpark) is an AI-native pharmaceutical company that acquires and develops clinical-stage drugs using a technology platform to accelerate every stage of drug development. Its AI and LLM-driven systems streamline clinical trial design, execution, and regulatory processes to bring treatments to patients faster and more efficiently.

HealthVerity operates a privacy-protected real-world healthcare data exchange and patient identity platform used by pharma, payers, and government organizations. In May 2026 it closed a $112.37M Series E and completed its acquisition of Symphony Health from ICON plc, uniting clinical and commercial healthcare data.

AI-based molecular interactions platform for drug discovery performing state-of-the-art structure prediction and antibody design

AI-first protein design company using deep generative models to create novel, functional proteins for applications in biomedicine, agriculture, and gene editing.

Ataraxis AI is a New York-based clinical AI research lab building multi-modal precision-medicine models that predict patient outcomes and treatment response. Its foundation models (Falcon, Kestrel) for digital pathology power products like Ataraxis Breast, an AI-native prognostic test for breast cancer. Founded in 2023 as an NYU spinout, it counts Yann LeCun among its founding advisors.

Biograph is a preventive health and longevity clinic combining advanced diagnostics, physician-led care, and long-term member programs to surface health risks early.

Colossal Biosciences is a genetic engineering and de-extinction company using CRISPR technology to restore extinct species like the woolly mammoth and protect critically endangered ecosystems.

Frontier AI company on a mission to solve breakthrough materials discovery using generative AI and advanced molecular simulations, compressing decades of R&D into months.

Medra develops autonomous AI-powered robotic scientists that run and refine laboratory experiments end-to-end, interfacing with standard lab tools to accelerate drug discovery and biological research.

Nudge is developing advanced whole-brain interfaces for everyday life using phased-array ultrasound-based wearable devices capable of both imaging and modulating brain activity, enabling at-home treatments for mood, memory, focus, and chronic conditions like pain, addiction, and anxiety.

Basecamp Research is a London-based biotech company that uses AI trained on a proprietary biodiversity database, built from global expeditions, to design novel proteins and therapeutics. It raised an oversubscribed $140M Series C in September 2026 led by S32, with participation from NVIDIA and Anthropic's Anthology Fund.

NewLimit develops epigenetic reprogramming medicines to restore youthful cellular function and treat diseases with large unmet needs. Co-founded by Brian Armstrong, the company targets liver, immune, and vascular systems.

Orchid offers whole-genome embryo screening and preconception genetic testing to help prospective parents reduce inherited disease risk.

AI foundation models platform focused on making biology programmable and accelerating protein design.

Verana Health is a digital health data company that turns real-world clinical data into research-grade insights for life sciences, providers, and regulators. It is exclusively entrusted by specialty medical societies (ophthalmology, neurology, urology) to curate registry and EHR data from 20,000+ providers across 70+ EHR systems. Its VeraQ population-health data engine and Qdata modules use AI-assisted curation to power drug development, label expansion, and post-market surveillance.

A biotechnology company developing carbon-negative polymers and materials using genetically engineered enzymes.

Mithrl builds a Scientific Decision Engine (Mithrl-1), a biomedical world model and agentic platform that helps biopharma R&D teams reason over validated biology from peer-reviewed literature and proprietary data. The San Francisco company aims to help teams move from idea to IND submission 50% faster.

Until Labs develops reversible cryopreservation technology to pause biological time, starting with organ-scale preservation to extend the viability of donor organs for transplantation. The company is building medical infrastructure toward whole-body medical hibernation technology.

Cradle builds an AI-powered protein engineering platform that helps biotech teams design and optimize proteins faster across discovery workflows.

Cresilon develops hemostatic medical devices, including gel-based technologies that rapidly stop bleeding for human and animal care.

Debut is a beauty biotechnology company that uses AI-powered ingredient discovery and biofermentation to create high-performing, sustainable beauty ingredients from molecules that nature produces only in minute quantities. Named one of TIME100 Most Innovative Companies in 2025, the company partners with major brands like L'Oreal to develop next-generation skincare actives with a focus on skin longevity. Headquartered in San Diego, Debut has raised over $89 million and screens billions of candidate molecules through its proprietary platform.

The first high-throughput in vivo discovery engine combining massively multiplexed in vivo screening and AI-powered design to create tissue-targeted medicines.

Angitia is a biotechnology company developing novel therapies for endocrine and metabolic diseases, including rare disease programs.

AI-powered drug discovery platform advancing nature-inspired therapeutics from plants and natural products into clinical development.

Novellia is a patient-powered health data platform that lets anyone in the US access and unify up to ~20 years of their complete medical history in under 30 seconds, for free. It turns that de-identified, patient-consented data into real-world data products for biopharma R&D, already working with several of the top 10 pharmaceutical companies. The company offers both a web platform and a patient-facing mobile app.

Phylo is an applied AI research laboratory developing Biomni Lab, an integrated workspace enabling scientists to plan, author, execute, and collaborate on complex biological research tasks with state-of-the-art agentic AI.

Valthos is an applied biological intelligence company developing AI and software to detect biological threats and design medical countermeasures in real time.

Albert Invent develops AI software for chemistry and materials R&D teams to accelerate formulation, experiment planning, and commercialization workflows.

Eli Health develops AI-based smart devices for women's reproductive health monitoring, offering a point-of-care device that provides instant hormone profiles from saliva samples. The technology enables continuous hormone monitoring for daily and lifelong health insights.

AI document generation platform for life sciences that automates regulatory paperwork for diagnostic, medical device, and drug development companies. Founded by Surbhi Sarna and Nate Smith.

Generation Lab is an AI biotechnology company building an agent scientist platform to program the immune system and accelerate antibody and cell therapy discovery.

Lindus Therapeutics (formerly Lindus Health) in-licenses clinical-stage therapeutic assets and develops them to value inflection points or approval. It began as a technology-first clinical research organization that ran 45+ trials, and in 2026 sold its CRO business to Curavit to focus on its own drug pipeline.

Loyal is a clinical-stage veterinary medicine company developing longevity drugs to help dogs live longer, healthier lives. They are the first company to receive FDA approval for a longevity drug candidate targeting aging in dogs.

Resilience (National Resilience, Inc.) is a contract development and manufacturing organization (CDMO) providing end-to-end biomanufacturing for biologics, vaccines, cell and gene therapies. Founded in 2020 and headquartered in Blue Ash, Ohio, it operates multiple facilities across North America and has raised over $2.5B in equity financing.

Teal Health is a San Francisco-based women's health company that created the Teal Wand, the first FDA-authorized self-collection device for at-home cervical cancer screening paired with telehealth support. The company aims to expand access to cervical cancer screening outside traditional clinical settings ahead of expected broad insurance coverage in 2027.

Cellular Intelligence (formerly Somite AI) builds foundation models for human stem cells to accelerate the development of cell therapies. Its DeltaStem platform uses proprietary high-throughput data generation to discover cell differentiation protocols for conditions like Type 1 diabetes, orthopedic injuries, and muscular dystrophy.

Contextual AI platform for life sciences and healthcare, providing a visual development environment for building enterprise AI applications across drug discovery, clinical development, and healthcare operations.

AI-native operating system for biopharma companies, unifying internal and external data, codifying decision logic, and generating critical deliverables across the drug development lifecycle.

Epicrispr Biotechnologies is a South San Francisco-based gene therapy company developing epigenetic medicines using its GEMS (Gene Expression Modulation System) platform, founded on CRISPR science from Stanford's Stanley Qi. Its lead program targets facioscapulohumeral muscular dystrophy (FSHD), a rare muscle-wasting disease, with an FDA-cleared IND for EPI-321.

Natural Cycles is the world's first FDA-cleared birth control app, using a proprietary algorithm and body temperature data to provide a non-hormonal, non-invasive contraceptive solution trusted by millions of women globally.

QuantHealth is a dual-HQ New York/Tel Aviv startup building an AI platform that simulates clinical trial outcomes, allowing pharma and biotech partners to run thousands of trial design variations to de-risk and accelerate drug development. It has simulated more than 600 clinical trials across 30 indications with up to 90% predictive accuracy.

Sennos builds AI software for fluidics and fermentation operations, focusing on process monitoring, optimization, and bioprocess analytics.

Cellares is an integrated development and manufacturing organization (IDMO) for cell therapies, using automation and industrial-scale manufacturing systems to expand access to life-saving treatments.

Discovery Loop is a Palo Alto public benefit corporation founded in August 2026 by ex-Google AI leaders Jeff Dean, Sanjay Ghemawat, Oriol Vinyals, and Quoc Le. It is building autonomous AI systems to automate the scientific method — proposing, running, and evaluating experiments at scale across machine learning, science, and engineering.

Kingdom Supercultures engineers microbes to create functional ingredients for food and beverage brands.

Aleph Neuro is a San Francisco research lab building non-invasive brain interfaces, aiming to read and transmit "latents" — raw thoughts — toward direct brain-to-brain communication. In June 2026 it publicly launched with what it claims are the highest-resolution 3D images of the human brain captured from outside the skull, delivering MRI-level detail without surgery or bulky hardware. The system is built on Butterfly Network's Ultrasound-on-Chip technology via the Butterfly Embedded licensing and co-development program.

Aniva is a personal health operating system offering comprehensive biomarker testing with 140+ markers, personalized supplement packs, doctor consultations, and ongoing health optimization with regular re-testing cycles.

Aptadir Therapeutics is a Milan, Italy-based preclinical biotech developing a new class of RNA inhibitor therapeutics called DNMT-interacting RNAs (DiRs) that block aberrant DNA methylation to reactivate silenced genes. Its lead candidate, CAP1-FMR1, targets Fragile X Syndrome, with additional programs in myelodysplastic syndrome and other cancers and rare genetic disorders. The science originates from Beth Israel Deaconess Medical Center, Italy's CNR, and the Cancer Science Institute of Singapore.

AtlasBase (formerly Atlas Data Storage) develops DNA-based data storage systems for ultra-long-term, resilient archival storage.

Bindwell is an AI-powered pesticide discovery company that uses machine learning models 4x faster than DeepMind's AlphaFold to screen billions of molecules and design safer, more effective crop protection products. Unlike traditional agtech software companies, Bindwell develops and licenses complete proprietary pesticide molecules to major agrochemical companies. Founded by teen entrepreneurs Tyler Rose and Navvye Anand through Y Combinator's W25 batch, the company is backed by General Catalyst and Paul Graham.

A scalable biological data collection service providing multi-omics data for research.

BrainChild Bio is a Seattle-based clinical-stage biotech spun out of Seattle Children's, developing CAR T cell therapies for pediatric brain and CNS tumors. Its lead program targets diffuse intrinsic pontine glioma (DIPG), building on research from Dr. Michael Jensen's lab, and it closed a $116M Series A to fund a pivotal Phase 2 trial.

Breakthru Medicine is a biotech company developing novel oncology therapies, with a focus on first-in-class radioconjugate treatment approaches for cancer.

Caris Life Sciences is a molecular science and technology company specializing in molecular profiling of cancer and other complex diseases to enable precision medicine. It offers tumor profiling, blood-based diagnostics, and AI-driven analytics for oncologists and biopharma partners.

Coincidence Labs builds an agentic AI platform for pharmaceutical R&D, enabling scientists to search, synthesize, and explain molecular insights with literature-backed evidence. Its product serves as an AI copilot for extracting insights from patents, scientific literature, and related documents to accelerate research decisions.

Converge Bio develops generative AI platform trained on molecular data to help pharma and biotech companies discover and develop more effective drugs faster, utilizing Large Language Models specifically trained on biological languages.

Cortical Labs builds biological computers by integrating lab-grown human neurons with silicon chips. Their CL1 system represents the first commercial biological computer, enabling energy-efficient computation through living neural networks for AI and scientific research applications.

DermaSensor develops an FDA-cleared, handheld AI-and-spectroscopy device that helps primary care physicians assess suspicious skin lesions for skin cancer risk at the point of care. The company is expanding US distribution through partnerships with Henry Schein and other healthcare and federal health system partners.

Encoded Therapeutics develops precision genetic medicines for severe neurological disorders, using a cell-selective targeting and regulation platform. Its lead program, ETX101, targets Dravet syndrome and is advancing through pivotal clinical development from South San Francisco.

Expert Intelligence builds an AI decision layer for laboratory workflows in pharma, materials, food, and environmental testing, emphasizing governed and traceable decisions.

Guardian Bio is a biotech company developing dendritic cell-based therapies designed to restore anti-tumor immune responses in cancer patients.

Secretive UK-based AI biotech co-founded by former Google CEO Eric Schmidt, spun out of University College London and King's College London. It builds "large medicine models" that account for biological variation across patients to unmask true treatment effects and de-risk late-stage clinical trials and drug development.

Kivo provides regulatory, quality, and clinical document management software for emerging life sciences teams, with workflows for compliant collaboration and submissions.

Metabolic health company that uses continuous glucose monitoring technology and AI-powered software to help users understand how food, exercise, and sleep affect their bodies in real time.

Mantis Biotech builds infrastructure powering human-in-computer models, combining LLMs with high-fidelity physics simulations to convert rare human behavior data into predictive digital twins. The platform unifies fragmented biological, performance, and operational data into a single interactive system. Initially focused on sports health and human performance, the technology applies broadly to any domain where decisions are critical and data is complex.

Moonwalk Biosciences is a biotech company developing precision epigenetic medicines that reprogram the epigenome to treat aging-related and genetic diseases. Co-founded by former Illumina CTO Alex Aravanis and Broad Institute scientist Feng Zhang, it is backed by Khosla Ventures, ARCH Venture Partners, GV, and others.

Regenerative medicine company developing stem cell-derived tissue and organ replacement therapies for liver disease using iPSC-derived platform technology, with operations in Montreal, Cambridge and Toronto

Nilo Therapeutics is a New York-based biotech developing a new class of medicines that harness brain-body neural circuits to restore immune homeostasis. Building on Charles Zuker's Columbia lab discovery of vagal neurons that centrally regulate systemic inflammation, the company targets master-regulator circuits to treat autoimmune and inflammatory disease. Co-founded with The Column Group by Charles Zuker (Columbia), Ruslan Medzhitov (Yale), and Stephen Liberles (Harvard); Kim Seth is CEO.

Omanta runs a personalized research program — "a research lab for one" — for individual patients facing complex cancers, rare disease, or undiagnosed conditions. It integrates a patient's full medical record, personal genomics, AI analysis, and current clinical evidence to identify molecular drivers of disease, then evaluates existing and emerging therapies against that biology, developing personalized treatment campaigns (vaccines, immunotherapies, radioligands) when no suitable therapy exists. Founded in 2026 in San Francisco by Alfredo Gonzalez, PhD and Ranad Humeidi, PhD; part of Y Combinator's Summer 2026 batch.

Parasma is a San Francisco biocomputing startup that writes algorithms to train live human brain cells to act as a computing substrate for AI workloads. The founder previously got cultured human neurons to play Doom, and the company's claimed edge is the training methodology rather than proprietary wetware hardware. It is a Y Combinator Summer 2026 company, solo-founded and pre-product as of mid-2026.

Clinical trials access platform that matches patients to studies and streamlines enrollment for healthcare providers and life sciences teams.

Prometheus is a Physical AI company co-founded by Jeff Bezos and Vik Bajaj building an 'artificial general engineer' — AI that can design, experiment on, and manufacture complex physical products such as jet engines, drugs, and advanced materials. The company operates out of San Francisco, London, and Zurich, recruiting researchers from OpenAI, DeepMind, and Meta. It raised a $12B round in June 2026 at a ~$41B valuation, bringing total funding above $18B.

Prudentia Sciences develops AI software for life-sciences diligence, asset valuation, and investment decision support across biopharma programs.

AI biosecurity company developing AI-powered defenses against biological threats and bioweapons. Spun out from mRNA therapeutics company Helix Nano, partners with frontier AI labs to identify emerging bio-risks and design countermeasures using advanced models, lab automation, and reinforcement learning to scale biological defenses at the same rate as AI capabilities grow.

Sava Technologies is a London-based healthtech startup that has developed a wearable, pain-free multi-molecule biosensor for continuous glucose and health monitoring. Founded in 2019 by Imperial College London bioengineers Renato Circi and Rafaël Michali, it raised a $36M Series B led by Ascensia, which also became its European commercialization and distribution partner.

Science Corporation is a neural engineering company developing brain-computer interface (BCI) technology to restore and enhance human vision. The company's PRIMA retinal implant uses advanced neurotechnology to treat blindness caused by conditions like age-related macular degeneration, Stargardt disease, and retinitis pigmentosa. Founded by Neuralink co-founders Max Hodak and Alan Mardinly, Science has raised $489 million and is racing to become the first BCI company with a product in market.

Senticell develops liquid-biopsy diagnostics based on red-cell-bound nucleic acids, using technology licensed exclusively from the University of Pennsylvania. Its platform aims to detect disease across oncology, infection, and autoimmune conditions from molecular signals bound to red blood cells. The company is based in Princeton, New Jersey.

Slideflow Labs is a University of Chicago Medicine spinout building AI-powered digital biomarkers for cancer pathology. Its platform analyzes standard H&E pathology slides using foundation models to deliver quantitative, regulatory-grade biomarker insights to hospitals and biopharma without additional stains or specimens.

Solstice Oncology is a Boston-based, clinical-stage immuno-oncology company developing porustobart, a next-generation Fc-enhanced CTLA-4 antibody licensed from Harbour BioMed. Its lead program combines porustobart with anti-PD-1 therapy in the neoadjuvant setting for MSS stage II-III colon cancer, with a Phase 2 program underway.

Sway is a material innovation company that harnesses seaweed to create home-compostable replacements for single-use plastic packaging. Their patent-pending TPSea resin is 100% biobased and microplastic-free. Named TIME Best Invention of 2025.

Third Arc Bio is an immunology and inflammation-focused biotechnology company developing targeted immune therapeutics across oncology and inflammatory disease programs.

Throne is building an AI-powered smart toilet device that clips onto standard toilets and uses computer vision and sensors to continuously monitor gut health, hydration, and urological function. The device analyzes stool and urine biomarkers with every flush and delivers daily health insights via a mobile app without requiring manual sample collection. The company has research partnerships with the University of Chicago, MIT, and the Crohn's & Colitis Foundation.

Tracer is the first pipeline monitoring system purpose-built for high-performance computing in life sciences, providing real-time performance metrics, cost breakdowns, and optimization insights for complex computational pipelines.

Transfyr builds physical AI infrastructure that captures scientific work through sensors and multimodal models. Its platform converts laboratory execution into machine-readable data for reproducibility, automation, training, and technology transfer. The Cambridge, Massachusetts startup operates an in-house wet lab and is hiring technical staff.

Typewriter Therapeutics develops RNA-based, non-viral gene insertion medicines using its Target-Primed Reverse Transcription (TPRT) platform built on the R2 retrotransposon system. The company is pursuing durable, re-dosable gene therapies including in vivo CAR-T for cancer, autoimmune, and severe genetic diseases, with operations in Cambridge, Massachusetts and Tokyo.

Ultrahuman is a comprehensive health technology platform offering wearable devices including the Ring AIR for sleep and activity tracking, M1 continuous glucose monitoring, and Home environmental health monitoring. The company combines real-time biometric data with AI-driven insights.